Posted by Michael Wonder on 17 Jun 2022
Sierra Oncology announces submission of new drug application for momelotinib to US Food & Drug Administration
17 June 2022 - Submission seeks approval of momelotinib for the treatment of myelofibrosis.
Sierra Oncology today announced the company has submitted a new drug application to the US FDA for momelotinib, an ACVR1 / ALK2, JAK1 and JAK2 inhibitor in development for the treatment of myelofibrosis.
